Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Cures 2015

NJ Spotlight: House’s Cures 2015 Bill Holds Promise for ‘Personalized Medicine’

Montclair, NJ, May 26, 2015 ― Andrew Kitchenman reports in NJ Spotlight that the U.S. House’s 21st Century Cures Act is attracting bipartisan support — including from New Jersey sponsors Reps. Frank Pallone (D-6)  and Leonard Lance (R-7) — and draws praise across New Jersey’s research community, as well as its biotechnology and pharmaceutical industries.

They see its goals of increasing medical research funding and speeding the approval of new drugs and medical devices as essential to promoting therapies that will serve patients and promote the state’s biotech and pharma companies.

Lance sponsored a section of the bill that would ease limits on the amount of money that the Food and Drug Administration can spend to test drugs.  That would increase the speed at which the FDA can approve drugs. Continue reading

Rep. Lance Hails Committee Passage of 21st Century Cures Initiative; Package Included Protection of NJ Life Science Resources

Washington, DC, May 22, 2015 ― Congressman Leonard Lance (R-7) today hailed the work of the House Energy and Commerce Committee for its unanimous approval of bipartisan legislation, the 21st Century Cures Act (#Cures 2015).

Congressman Lance — a member of the Health Subcommittee and involved in the years-long process that led to the Committee’s action on Thursday—has long championed the fight for opening the innovation pipeline and bringing biomedical innovation to market faster and ensuring regulatory agencies and the private sector have the tools to create in the 21st century.

The 21st Century Cures Act included Lance’s legislation, the FDA Safety Over Sequestration Act (FDA SOS Act), which exempts Food and Drug Administration (FDA) user fees from sequestration and puts those resources back for the approval of drugs and medical devices. Continue reading